Genetic cheat code may unlock safer, stronger chemo cocktail for tough cancers

NCT ID NCT04361708

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try to reduce side effects. The main goal is to find the safest dose, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of five chemotherapy drugs: irinotecan, fluorouracil (5-FU), leucovorin, oxaliplatin, and docetaxel
What this could lead to
If successful, this could lead to a more effective chemotherapy regimen for advanced upper gastrointestinal cancers, tailored to a patient's genetic profile.
What could go wrong
This is an early Phase 1 trial with only 54 participants, focused on finding safe doses, not proving the treatment works. The combination of five strong chemotherapies may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.